United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

zentiva pharma uk ltd - risedronate sodium - oral tablet - 35mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - risedronate sodium - oral tablet - 35mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - risedronate sodium - oral tablet - 35mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - risedronate sodium - oral tablet - 35mg

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - risedronic acid

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - risedronate sodium anhydrous (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risedronate sodium delayed-release tablets are contraindicated in patients with the following conditions: - abnormalities of the esophagus which delay esophageal e

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industires inc. - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon

United States - English - NLM (National Library of Medicine)

northstar rxllc - risedronate sodium (unii: ofg5exg60l) (risedronic acid - unii:km2z91756z) - risedronate sodium delayed-release tablets are indicated for the treatment of osteoporosis in postmenopausal women. in postmenopausal women, risedronate sodium has been shown to reduce the incidence of vertebral fractures and a composite endpoint of nonvertebral osteoporosis-related fractures [see clinical studies (14.1) ]. the optimal duration of use has not been determined. the safety and effectiveness of risedronate sodium delayed-release tablets for the treatment of osteoporosis are based on clinical data of one year duration. all patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. patients at low-risk for fracture should be considered for drug discontinuation after 3 to 5 years of use. patients who discontinue therapy should have their risk for fracture re-evaluated periodically. risk summary available data on use of risedronate sodium in pregnant women are insufficient to inform drug-associated risk of adverse maternal or fetal outcomes. discon

Ireland - English - HPRA (Health Products Regulatory Authority)

zaklad farmaceutyczny adamed pharma s.a. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

accord healthcare ireland ltd. - risedronate sodium - film-coated tablet - 35 milligram(s) - bisphosphonates; risedronic acid